Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Accumulated Expenses for 6 consecutive years, with $116166.0 as the latest value for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 790.16% to $116166.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $116166.0 through Sep 2025, up 790.16% year-over-year, with the annual reading at $81000.0 for FY2024, 21.22% down from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $116166.0 at Inhibikase Therapeutics, up from $74316.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $2.7 million in Q3 2023, with the low at $100.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $178505.1, with a median of $13050.0 recorded in 2024.
  • Peak annual rise in Other Accumulated Expenses hit 25461.0% in 2024, while the deepest fall reached 99.52% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $5127.0 in 2021, then skyrocketed by 93.49% to $9920.0 in 2022, then soared by 936.46% to $102817.0 in 2023, then dropped by 21.22% to $81000.0 in 2024, then soared by 43.41% to $116166.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $116166.0, $74316.0, and $127703.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.